Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIELLE M BRANDER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1144497553
CMS profile
233269
Location
DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$10,733.28

21 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Verastem, Inc. $8,902.42 16
Genentech, Inc. $1,300.00 1
PFIZER INC. $335.99 2
Genentech USA, Inc. $116.86 1
AbbVie, Inc. $78.01 1

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIELLE M BRANDER

NPI 1144497553 · CMS profile ID 233269

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144497553?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIELLE M BRANDER, NPI 1144497553, CMS profile ID 233269. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144497553?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). DANIELLE M BRANDER, NPI 1144497553, CMS profile ID 233269. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144497553?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
DANIELLE M BRANDER, NPI 1144497553, CMS profile ID 233269, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1144497553?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

21 matching records · $10,733.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 21 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–21 of 21.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie, Inc. $78.0112/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648087005 CMS
Genentech USA, Inc. $116.8612/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681141929 CMS
PFIZER INC. $128.3412/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673853115 CMS
PFIZER INC. $207.6512/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673853117 CMS
Verastem, Inc. $2,175.0010/17/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791377 CMS
Verastem, Inc. $44.0008/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791357 CMS
Verastem, Inc. $47.7708/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791361 CMS
Verastem, Inc. $5,075.0007/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791317 CMS
Verastem, Inc. $75.4106/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791327 CMS
Verastem, Inc. $252.0006/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791331 CMS
Verastem, Inc. $75.1006/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791334 CMS
Verastem, Inc. $113.8506/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791337 CMS
Verastem, Inc. $30.0006/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791341 CMS
Verastem, Inc. $25.0006/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791345 CMS
Verastem, Inc. $47.2606/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791349 CMS
Verastem, Inc. $78.5406/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791353 CMS
Verastem, Inc. $77.3706/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791371 CMS
Verastem, Inc. $428.6006/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791321 CMS
Verastem, Inc. $282.1106/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791323 CMS
Verastem, Inc. $75.4106/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791367 CMS
Genentech, Inc. $1,300.0003/04/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681168447 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,733.28 21
PY2020 $1,676.00 2
PY2024 $6,544.07 5
PY2025 $2,537.50 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,449,633.69 67
PY2024 Principal investigator $2,178,707.78 124
PY2023 Principal investigator $670,662.81 39
PY2022 Principal investigator $319,423.50 21
PY2021 Recipient $15.58 1
PY2021 Principal investigator $1,263,815.47 56
PY2020 Principal investigator $2,651,847.30 70
PY2019 Principal investigator $68,831.32 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

124 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Celgene Corporation $2,451.19 12/20/2024 Non-covered Recipient Entity
Duke Occupational & Envir Med
TRANSCEND 3L+ CLL- 17004 (Ph 1/2) - An Open-Label, Phase 1/2 Study Of JCAR017 In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma (017004) No dispute reported 06/30/2026 1155549995
Principal investigator 1 BeiGene, Ltd. $154.20 12/16/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119731029
Principal investigator 1 BeiGene, Ltd. $449.75 12/12/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119719501
Principal investigator 1 BeiGene, Ltd. $25.70 12/12/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119719503
Principal investigator 1 BeiGene, Ltd. $1,474.00 12/11/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies No dispute reported 06/30/2026 1119726735
Principal investigator 1 BeiGene, Ltd. $16,483.68 12/02/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119729000
Principal investigator 1 BeiGene, Ltd. $22,633.00 11/26/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119715745
Principal investigator 1 BeiGene, Ltd. $8,241.84 11/25/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119719817
Principal investigator 1 BeiGene, Ltd. $142,740.70 11/25/2024 Non-covered Recipient Entity
Duke University ,
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 1119725049
Principal investigator 1 BeiGene, Ltd. $8,241.84 11/21/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119719803
Principal investigator 1 BeiGene, Ltd. $32,967.36 11/19/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119728697
Principal investigator 1 BeiGene, Ltd. $3,597.44 11/12/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119731005
Principal investigator 1 BeiGene, Ltd. $45,360.00 11/12/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119731007
Principal investigator 1 BeiGene, Ltd. $16,483.68 11/11/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119730977
Principal investigator 1 BeiGene, Ltd. $32,967.36 10/21/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119719711
Principal investigator 1 BeiGene, Ltd. $6,680.96 10/21/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119719713
Principal investigator 1 BeiGene, Ltd. $179.90 10/21/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119719715
Principal investigator 1 BeiGene, Ltd. $449.75 10/21/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119719717
Principal investigator 1 BeiGene, Ltd. $30,240.00 10/21/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119719719
Principal investigator 1 BeiGene, Ltd. $149,236.90 10/21/2024 Non-covered Recipient Entity
Duke University ,
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 1119725047
Principal investigator 1 BeiGene, Ltd. $1,322.00 10/16/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies No dispute reported 06/30/2026 1119726619
Principal investigator 1 BeiGene, Ltd. $750.00 08/30/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119714849
Principal investigator 1 BeiGene, Ltd. $1,250.00 08/30/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119729554
Principal investigator 1 Celgene Corporation $15,616.56 08/21/2024 Non-covered Recipient Entity
Duke University Health System
TRANSCEND 3L+ CLL- 17004 (Ph 1/2) - An Open-Label, Phase 1/2 Study Of JCAR017 In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma (017004) No dispute reported 06/30/2026 1155550243
Principal investigator 1 BeiGene, Ltd. $29,531.30 07/29/2024 Non-covered Recipient Entity
Duke University ,
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 1119725045
Principal investigator 1 BeiGene, Ltd. $6,963.00 07/29/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119725135
Principal investigator 1 BeiGene, Ltd. $21,830.00 07/29/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119725137
Principal investigator 1 BeiGene, Ltd. $2,249.35 07/29/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119725139
Principal investigator 1 BeiGene, Ltd. $3,200.00 07/29/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119725141
Principal investigator 1 BeiGene, Ltd. $4,788.00 07/29/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119725143
Principal investigator 1 BeiGene, Ltd. $1,340.00 07/22/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119714665
Principal investigator 1 BeiGene, Ltd. $2,713.00 07/17/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies No dispute reported 06/30/2026 1119714479
Principal investigator 1 BeiGene, Ltd. $678.00 07/17/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies No dispute reported 06/30/2026 1119714861
Principal investigator 1 BeiGene, Ltd. $1,500.00 07/17/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies No dispute reported 06/30/2026 1119723873
Principal investigator 1 BeiGene, Ltd. $1,250.00 07/17/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies No dispute reported 06/30/2026 1119723875
Principal investigator 1 BeiGene, Ltd. $3,325.00 07/17/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies No dispute reported 06/30/2026 1119724213
Principal investigator 1 BeiGene, Ltd. $1,474.00 06/28/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies No dispute reported 06/30/2026 1119713971
Principal investigator 1 BeiGene, Ltd. $2,737.14 06/28/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721211
Principal investigator 1 BeiGene, Ltd. $452.20 06/28/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies No dispute reported 06/30/2026 1119723141
Principal investigator 1 BeiGene, Ltd. $2,324.84 06/28/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119729368
Principal investigator 1 BeiGene, Ltd. $2,450.00 06/26/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119722521
Principal investigator 1 BeiGene, Ltd. $10,080.00 06/26/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119729352
Principal investigator 1 BeiGene, Ltd. $179.90 06/20/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119719577
Principal investigator 1 BeiGene, Ltd. $80,206.30 06/04/2024 Non-covered Recipient Entity
Duke University ,
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 1119725043
Principal investigator 1 BeiGene, Ltd. $1,322.00 05/31/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies No dispute reported 06/30/2026 1119720937
Principal investigator 1 BeiGene, Ltd. $1,322.00 05/31/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies No dispute reported 06/30/2026 1119721371
Principal investigator 1 BeiGene, Ltd. $60,480.00 05/28/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119719381
Principal investigator 1 BeiGene, Ltd. $60,480.00 05/28/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119719383
Principal investigator 1 BeiGene, Ltd. $14,389.76 05/28/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119719385
Principal investigator 1 BeiGene, Ltd. $14,389.76 05/28/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119719387
Principal investigator 1 BeiGene, Ltd. $179.90 05/28/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119719389
Principal investigator 1 BeiGene, Ltd. $179.90 05/28/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119719391
Principal investigator 1 BeiGene, Ltd. $3,148.32 05/28/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119719393
Principal investigator 1 BeiGene, Ltd. $3,148.32 05/28/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119719395
Principal investigator 1 BeiGene, Ltd. $32,967.36 05/28/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1119719397
Principal investigator 1 BeiGene, Ltd. $1,322.00 04/26/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies No dispute reported 06/30/2026 1119723285
Principal investigator 1 BeiGene, Ltd. $39,021.70 04/05/2024 Non-covered Recipient Entity
Duke University ,
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 1119726803
Principal investigator 1 BeiGene, Ltd. $2,324.84 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119719869
Principal investigator 1 BeiGene, Ltd. $93.10 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119719887
Principal investigator 1 BeiGene, Ltd. $905.73 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119719893
Principal investigator 1 BeiGene, Ltd. $905.73 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119719899
Principal investigator 1 BeiGene, Ltd. $239.40 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119719921
Principal investigator 1 BeiGene, Ltd. $226.10 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119719957
Principal investigator 1 BeiGene, Ltd. $905.73 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119719967
Principal investigator 1 BeiGene, Ltd. $226.10 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119719969
Principal investigator 1 BeiGene, Ltd. $239.40 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119719981
Principal investigator 1 BeiGene, Ltd. $905.73 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119719985
Principal investigator 1 BeiGene, Ltd. $226.10 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119719999
Principal investigator 1 BeiGene, Ltd. $905.73 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119720001
Principal investigator 1 BeiGene, Ltd. $2,324.84 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119720013
Principal investigator 1 BeiGene, Ltd. $905.73 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119720055
Principal investigator 1 BeiGene, Ltd. $905.73 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119720077
Principal investigator 1 BeiGene, Ltd. $226.10 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119720085
Principal investigator 1 BeiGene, Ltd. $436.24 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119720099
Principal investigator 1 BeiGene, Ltd. $905.73 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119720121
Principal investigator 1 BeiGene, Ltd. $436.24 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119720163
Principal investigator 1 BeiGene, Ltd. $589.19 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119720251
Principal investigator 1 BeiGene, Ltd. $905.73 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119720279
Principal investigator 1 BeiGene, Ltd. $2,743.79 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119720311
Principal investigator 1 BeiGene, Ltd. $905.73 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119720359
Principal investigator 1 BeiGene, Ltd. $905.73 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721533
Principal investigator 1 BeiGene, Ltd. $905.73 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721557
Principal investigator 1 BeiGene, Ltd. $905.73 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721567
Principal investigator 1 BeiGene, Ltd. $905.73 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721581
Principal investigator 1 BeiGene, Ltd. $226.10 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721589
Principal investigator 1 BeiGene, Ltd. $212.80 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721591
Principal investigator 1 BeiGene, Ltd. $917.70 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721607
Principal investigator 1 BeiGene, Ltd. $589.19 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721609
Principal investigator 1 BeiGene, Ltd. $359.10 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721721
Principal investigator 1 BeiGene, Ltd. $917.70 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721739
Principal investigator 1 BeiGene, Ltd. $2,743.79 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721767
Principal investigator 1 BeiGene, Ltd. $905.73 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721771
Principal investigator 1 BeiGene, Ltd. $905.73 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721789
Principal investigator 1 BeiGene, Ltd. $2,052.19 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721805
Principal investigator 1 BeiGene, Ltd. $575.89 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721831
Principal investigator 1 BeiGene, Ltd. $226.10 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721833
Principal investigator 1 BeiGene, Ltd. $365.75 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721865
Principal investigator 1 BeiGene, Ltd. $2,052.19 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721875
Principal investigator 1 BeiGene, Ltd. $905.73 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721887
Principal investigator 1 BeiGene, Ltd. $3,637.55 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721895
Principal investigator 1 BeiGene, Ltd. $379.05 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721901
Principal investigator 1 BeiGene, Ltd. $2,757.09 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721977
Principal investigator 1 BeiGene, Ltd. $2,743.79 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119729064
Principal investigator 1 BeiGene, Ltd. $905.73 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119729096
Principal investigator 1 BeiGene, Ltd. $905.73 03/15/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119729098
Principal investigator 1 BeiGene, Ltd. $750.00 02/29/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1119719947
Principal investigator 1 BeiGene, Ltd. $7,182.00 02/29/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1119719993
Principal investigator 1 BeiGene, Ltd. $1,111.00 02/29/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1119720107
Principal investigator 1 BeiGene, Ltd. $2,500.00 02/29/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1119720261
Principal investigator 1 BeiGene, Ltd. $3,000.00 02/29/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1119720291
Principal investigator 1 BeiGene, Ltd. $399.00 02/29/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1119720349
Principal investigator 1 BeiGene, Ltd. $1,330.00 02/29/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1119720365
Principal investigator 1 BeiGene, Ltd. $4,788.00 02/29/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1119721523
Principal investigator 1 BeiGene, Ltd. $665.00 02/29/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1119721551
Principal investigator 1 BeiGene, Ltd. $2,500.00 02/29/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1119721627
Principal investigator 1 BeiGene, Ltd. $7,448.00 02/29/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1119721903
Principal investigator 1 BeiGene, Ltd. $3,075.30 02/27/2024 Non-covered Recipient Entity
Duke University ,
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 1119726797
Principal investigator 1 BeiGene, Ltd. $1,025.10 02/12/2024 Non-covered Recipient Entity
Duke University ,
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 1119726795
Principal investigator 1 BeiGene, Ltd. $82,520.00 02/02/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119719949
Principal investigator 1 BeiGene, Ltd. $768,175.33 02/02/2024 Non-covered Recipient Entity
Duke University ,
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1119721867
Principal investigator 1 BeiGene, Ltd. $2,312.00 01/24/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1119720179
Principal investigator 1 BeiGene, Ltd. $4,283.00 01/24/2024 Non-covered Recipient Entity
Duke University ,
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1119729124
Principal investigator 1 BeiGene, Ltd. $167,402.90 01/19/2024 Non-covered Recipient Entity
Duke University ,
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 1119726791
Principal investigator 1 BeiGene, Ltd. $118,324.00 01/19/2024 Non-covered Recipient Entity
Duke University ,
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 1119726793